[Clinical implication of p53 analysis on DNA-damaging therapies of human gastric and rectal cancers].
Fujiwara
T
T
First Dept. of Surgery, Okayama University Medical School, Japan.
Tanaka
N
N
Hizuta
A
A
Gochi
A
A
Hamada
M
M
Takahashi
K
K
Takakura
N
N
Orita
K
K
D000230:Adenocarcinoma / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology / Q000532:radiotherapy; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017209:Apoptosis; D002945:Cisplatin / Q000008:administration & dosage; D004249:DNA Damage; D004317:Doxorubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012004:Rectal Neoplasms / Q000235:genetics* / Q000473:pathology / Q000532:radiotherapy; D013274:Stomach Neoplasms / Q000188:drug therapy / Q000235:genetics* / Q000473:pathology; D016159:Tumor Suppressor Protein p53 / Q000032:analysis* / Q000235:genetics
D016159:Tumor Suppressor Protein p53; D005047:Etoposide; D004317:Doxorubicin; D002945:Cisplatin